Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. - Wikidata - awgldk - TriplyDB

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

http://www.wikidata.org/entity/Q34578231

about

Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials Oxidation of marine omega-3 supplements and human health Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association Effects of some common food constituents on cardiovascular disease Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk Should patients with cardiovascular disease take fish oil?Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease Omega-3 polyunsaturated fatty acid supplementation in the prevention of cardiovascular disease Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus Comparison of bioavailability of krill oil versus fish oil and health effect ω-3 Fatty Acids and Cardiovascular Diseases: Effects, Mechanisms and Dietary Relevance Anti-Inflammatory Diet for Atherosclerosis and Coronary Artery Disease: Antioxidant Foods Omega-3 Polyunsaturated Fatty Acids: The Way Forward in Times of Mixed Evidence Origin and therapy for hypertriglyceridaemia in type 2 diabetes Omega-3 supplements and cardiovascular diseases Residual macrovascular risk in 2013: what have we learned?Lipid-lowering agents in the management of nonalcoholic fatty liver disease Treatment of dyslipidemia Preservation of metabolic flexibility in skeletal muscle by a combined use of n-3 PUFA and rosiglitazone in dietary obese mice Omega-3s and cardiovascular health.Dietary intake of total marine n-3 polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid and the risk of acute coronary syndrome - a cohort study.Combining pain therapy with lifestyle: the role of personalized nutrition and nutritional supplements according to the SIMPAR Feed Your Destiny approach Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits?New Era of Lipid-Lowering Drugs Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia Nutrient reference value: non-communicable disease endpoints--a conference report Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 2 Alpha-linolenic acid: an omega-3 fatty acid with neuroprotective properties-ready for use in the stroke clinic?Sustainable source of omega-3 eicosapentaenoic acid from metabolically engineered Yarrowia lipolytica: from fundamental research to commercial production Overview of prescription omega-3 fatty acid products for hypertriglyceridemia Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid Preventive or potential therapeutic value of nutraceuticals against ionizing radiation-induced oxidative stress in exposed subjects and frequent fliers An ω-3-enriched diet alone does not attenuate CCl4-induced hepatic fibrosis Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in patients with a previous myocardial infarction: a randomised controlled trial A Comparative Overview of Prescription Omega-3 Fatty Acid Products

P2860

Q21092321-64FF8F96-2BE4-433A-8B96-D78D937697F8 Q21284850-CEB852BF-4EC7-42C7-AD89-C797703AED0C Q22306356-BE2245DA-B700-45E5-A460-21D0058983EF Q24605384-9C7D8DA5-8FCD-4F88-B830-27EB0A3F32D3 Q24608464-EED5F5CE-9000-4961-902B-BBDB6C50C7A4 Q24613094-23058C08-D2ED-475A-9875-D0C90C0F75E5 Q24626884-1F2EAEEB-400B-4089-9828-AD09BF2786E9 Q24669570-695985F2-92AE-4E28-AD14-D394602589E7 Q26738281-2B777E5A-0C78-4657-BDF2-C518A8F76306 Q26740508-D8AA0488-5C36-4A35-A262-1E3B7070477C Q26745946-16203156-6E11-4DDF-8B6E-CA102FE0203D Q26747026-697D0124-F2CA-4AF9-AB9E-02F456C33BE7 Q26747475-F1D860D1-1121-42DF-B2C5-01A6FBC2A2F2 Q26752919-C7F28606-1D2E-4CC2-8D1C-85D0595E36DA Q26781855-638C2274-B695-4273-B43A-26C76EC311AE Q26782277-08014E7B-7D80-4384-9A43-F3FF80535E06 Q26798027-CBD193C9-AF7B-4A76-B6D5-99206779B680 Q26798057-87020120-A0EF-4785-8187-652B0ECF2669 Q26824004-BCF81786-A379-47C6-A3A7-4E102D4380E6 Q26864908-2AB15F61-F20D-429F-B1CB-1E7B53587668 Q26996039-42970701-714D-43A1-ADBE-DBEE86E07474 Q27024352-131195FC-CA44-470A-9FE7-774473B65A57 Q27026114-1604BC0D-43AF-40BC-BC5C-D8616972A306 Q27322378-5E50853E-2BDC-46B6-AC91-A81BE661F09F Q27686781-9EB1CD69-B2F1-444D-B195-CCB5749D9952 Q27863412-55ED8AC1-173B-4DC8-BAE3-2B4F9C7EA0D1 Q28068212-8A709C73-3220-4D2A-A414-EA4895902F66 Q28069946-8341FD7D-6DCB-4C55-9FCB-92E8BCC36924 Q28072298-707D333D-B665-4F9B-AA9C-FF1C2B00AB8E Q28076399-05BEAC47-7969-46D7-84DF-54D77CE1EF6E Q28078517-DF2B59B5-4C33-449E-94F5-25FE692B6B92 Q28080258-B2826971-0898-4CF0-A8A0-F1EC966FB35C Q28085176-CEAA7B31-604E-46FB-B91D-2077301B846F Q28087179-2DB628C1-5021-4413-AAB4-D0AD725FC465 Q28251391-097C2490-BF6F-4A60-9142-6A5288B12028 Q28252451-8F0A94BE-0DD4-4F7D-AEB8-3957766EC1EF Q28388032-3B99A538-2383-4106-9EE9-A99F7EA62D6B Q28393724-C821CF64-D3C4-486A-8C98-F5BDF502B6FD Q28677739-7763BE98-7922-42C7-B74A-E10578D2B69E Q28972330-6C8B61F5-F78F-4F78-AACE-A82AB6F0A56A

P2860

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

http://www.wikidata.org/entity/Q34578231

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Effects of eicosapentaenoic ac ...... el, blinded endpoint analysis.

@ast

Effects of eicosapentaenoic ac ...... el, blinded endpoint analysis.

@en

Effects of eicosapentaenoic ac ...... el, blinded endpoint analysis.

@nl

type

label

Effects of eicosapentaenoic ac ...... el, blinded endpoint analysis.

@ast

Effects of eicosapentaenoic ac ...... el, blinded endpoint analysis.

@en

Effects of eicosapentaenoic ac ...... el, blinded endpoint analysis.

@nl

prefLabel

Effects of eicosapentaenoic ac ...... el, blinded endpoint analysis.

@ast

Effects of eicosapentaenoic ac ...... el, blinded endpoint analysis.

@en

Effects of eicosapentaenoic ac ...... el, blinded endpoint analysis.

@nl

P1433

Q34578231-70D61512-D258-4BE5-9B97-11915C3C2D34

P1476

Q34578231-C4AA9BE2-B99F-45EF-8219-90FE332B4670

P2093

Q34578231-01C8F8FA-4F93-4B8F-A89B-81DCD82AB3C8

Q34578231-0CA4ADC2-5823-4A1E-9BEC-413CC78EB681

Q34578231-2E57F006-2CD8-4B16-BE27-9C5699523737

Q34578231-34BB6645-C58C-4A09-986D-5AB9EFF4FAC5

Q34578231-3E629A29-4BF3-4BDD-AFC8-50A6CB368FDC

Q34578231-4C39FA2C-9842-4C2F-A9DD-715AE9A91F45

Q34578231-4DF8B260-E58D-4EAD-8E5C-AC23F92C6EF7

Q34578231-6BF10052-1F76-425F-949B-95722481C7A2

Q34578231-73555DEC-DCBF-4FDC-99C0-80A29042183D

Q34578231-745CDE21-1B0D-45DF-9AFC-E2E703C386DB

P304

Q34578231-E656F0B0-F5D3-425D-BCB6-02F142C86D2A

P31

Q34578231-64BFE219-7257-4473-AF61-F5CFF086E5C1

P356

Q34578231-1B4F22AE-FEB8-4941-BBDB-90A6940CE88D

P407

Q34578231-88FE5498-C3A5-4299-8A27-E0CB514A2682

P433

Q34578231-7EE6D409-30A1-4A5B-9E5F-848FF63AC4D7

P478

Q34578231-A89E2330-657B-4359-9B04-A20355EA6E83

P577

Q34578231-85B50EE3-658E-484F-B2A8-CF9D534BFEBD

P698

Q34578231-1641AD6B-85BE-4E61-B925-6010FC213AA9

P921

Q34578231-6F31825F-388D-41EF-8CA4-2669C1AB0ED1

P356

S0140-6736(07)60527-3

P1433

P1476

Effects of eicosapentaenoic ac ...... el, blinded endpoint analysis.

@en

P2093

Akira Kitabatake

http://www.w3.org/2001/XMLSchema#string

Hideki Origasa

http://www.w3.org/2001/XMLSchema#string

Hiroshige Itakura

http://www.w3.org/2001/XMLSchema#string

Hitoshi Hishida

http://www.w3.org/2001/XMLSchema#string

Japan EPA lipid intervention study (JELIS) Investigators

http://www.w3.org/2001/XMLSchema#string

Jun Sasaki

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Shimada

http://www.w3.org/2001/XMLSchema#string

Kunio Shirato

http://www.w3.org/2001/XMLSchema#string

Masunori Matsuzaki

http://www.w3.org/2001/XMLSchema#string

Mitsuhiro Yokoyama

http://www.w3.org/2001/XMLSchema#string

P304

1090-1098

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(07)60527-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

9567

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17398308

http://www.w3.org/2001/XMLSchema#string

P921

hypercholesterolemia